- The FDA accepts for review the New Drug Application (NDA) from Allergan (NYSE:AGN) seeking approval of oxymetazoline HCl cream 1.0% for the treatment of persistent facial erythema (redness) associated with rosacea in adults. The FDA's action date (PDUFA) should be in H1 2017.
- Rosacea is a chronic skin condition affecting more than 16M Americans. It generally affects adults between the ages of 30 and 60 years of age.